---Corcept Therapeutics----------- - 500 Beiträge pro Seite
eröffnet am 22.06.07 20:39:07 von
neuester Beitrag 22.06.07 22:40:43 von
neuester Beitrag 22.06.07 22:40:43 von
Beiträge: 11
ID: 1.129.259
ID: 1.129.259
Aufrufe heute: 0
Gesamt: 3.200
Gesamt: 3.200
Aktive User: 0
ISIN: US2183521028 · WKN: 529882 · Symbol: CORT
22,800
USD
+2,66 %
+0,590 USD
Letzter Kurs 26.04.24 Nasdaq
Neuigkeiten
24.04.24 · globenewswire  |
22.04.24 · globenewswire |
15.04.24 · globenewswire |
08.04.24 · globenewswire |
01.04.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 7,5400 | +47,55 | |
| 0,5922 | +44,44 | |
| 11,870 | +43,01 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,6700 | -12,17 | |
| 10,110 | -13,44 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Feedback
Gestern bekam die Aktie einen Schub, der sich heute fortsetzte bis 2,46 und wieder konsolidierte bis 2,04 $
Grund war der Artikel vom 21.06.2007
-------------------------------------------
June 21, 2007 - 9:00 AM EDT
Print Email Article Font Down Font Up Charts
close
Email this News Article
Your Name
Your Email
Friend\'s Name
Friend\'s Email
Receive Copy: yes
CORT 2.0722 0.3222
Today 5d 1m 3m 1y 5y 10y
Corcept Therapeutics Announces Positive Results From Its Proof of Concept Study Evaluating the Ability of CORLUX(R) to Mitigate Weight Gain Associated With Olanzapine
Corcept Therapeutics (NASDAQ: CORT) today announced that preliminary top line results indicated a statistically significant reduction in weight gain in those subjects who took olanzapine plus CORLUX compared to those who took olanzapine alone in a randomized, two week, double-blind, placebo controlled, proof of concept study.
In this study, 57 lean, healthy men (body mass index of 25 or less) were randomized to receive either olanzapine plus placebo (n=22), olanzapine plus CORLUX (n=24) or CORLUX plus placebo (n=11). This study took place in an institutional setting where daily weights were recorded and a range of metabolic parameters were measured. In the two-week study, subjects in the olanzapine alone group gained an average of 2.5 pounds more than subjects in the olanzapine plus CORLUX group and 2.2 pounds more than subjects in the CORLUX alone group, highly statistically significant differences (p < .001). The difference in weight gain trajectory was apparent in the first days of the study, reaching statistical significance during the first week. A preliminary review also indicates that for those patients who experienced a rise in fasting insulin and rise in triglycerides while taking olanzapine, the addition of CORLUX appears to have a beneficial effect; further analyses of these variables will be completed in the coming weeks. Although no unexpected study drug related adverse events were seen in any group, a complete review of all safety data has not yet been completed.
The group of medications known as atypical antipsychotics, including olanzapine, risperidone, clozapine and quetiapine, are widely used to treat schizophrenia and bipolar disorder. All medications in this group are associated with treatment emergent weight gain of varying degrees and carry a warning label relating to treatment emergent hyperglycemia and diabetes mellitus.
\"Weight gain and alterations in metabolic efficiency have been observed for many years in patients with abnormally high circulating cortisol. It is possible that a cortisol receptor antagonist like CORLUX may affect these characteristics in patients who take atypical antipsychotic medication,\" said Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept. \"This study begins to give us some insight into the possible causes of weight gain associated with atypical antipsychotic medications, and potentially may lead us towards a treatment.\"
Corcept previously announced results from two preclinical studies conducted in a rat model of olanzapine induced weight gain. These studies demonstrated that CORLUX reduced both the weight gain associated with ongoing olanzapine use and prevented the weight gain associated with the initiation of treatment with olanzapine. \"Because findings in animal studies do not always translate into human experience, we are pleased to see that the effect of CORLUX in our proof of concept study appears to replicate the experimental animal data,\" said Robert L. Roe, M.D, President of Corcept.
Eli Lilly and Company supported this proof of concept clinical study through an Investigator Initiated Trial grant and provided olanzapine for the study.
The combination of olanzapine and CORLUX is not approved for any indication and Lilly has no plans to pursue the use of combination CORLUX and olanzapine commercially. The purpose of this study was to explore the hypothesis that GR-II antagonists might mitigate weight gain associated with atypical antipsychotic medications.
Intellectual Property Portfolio
Corcept has developed an extensive intellectual property portfolio that covers the use of GR-II antagonists in the treatment of severe psychotic and metabolic disorders, including the prevention of weight gain caused by the use of antipsychotic medications. The company has also discovered and filed patents for three different series of compounds which block cortisol\'s activity at the GR-II receptor but do not block the progesterone receptor. \"Eventually, we hope to test and develop our new GR-II antagonists in a wide variety of disorders including the mitigation of weight gain associated with atypical antipsychotics,\" said James N. Wilson, Chairman of the Board of Corcept.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for severe psychiatric and metabolic disorders. The company\'s lead program is the development of CORLUX for the treatment of the psychotic symptoms of psychotic depression. For additional information about the company, please visit www.corcept.com.
Statements made in this news release, other than statements of historical fact, are forward-looking statements, including, for example, statements relating to Corcept\'s clinical development programs, and its spending plans. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. For example, there can be no assurances with respect to the commencement, cost, rate of spending, completion or success of clinical trials; financial projections may not be accurate; there can be no assurances that the investigations for future clinical trials will be completed, or that Corcept will pursue further activities with respect to clinical development of CORLUX. These and other risk factors are set forth in the Company\'s SEC filings, all of which are available from our website (www.corcept.com) or from the SEC\'s website (www.sec.gov). We disclaim any intention or duty to update any forward-looking statement made in this news release.
CONTACT:
Joseph K. Belanoff, M.D.
Chief Executive Officer
Corcept Therapeutics
650-327-3270
Email Contact
www.corcept.com
Source: Market Wire (June 21, 2007 - 9:00 AM EDT)
News by QuoteMedia
www.quotemedia.com
-----------------------------------------
Grund war der Artikel vom 21.06.2007
-------------------------------------------
June 21, 2007 - 9:00 AM EDT
Print Email Article Font Down Font Up Charts
close
Email this News Article
Your Name
Your Email
Friend\'s Name
Friend\'s Email
Receive Copy: yes
CORT 2.0722 0.3222
Today 5d 1m 3m 1y 5y 10y
Corcept Therapeutics Announces Positive Results From Its Proof of Concept Study Evaluating the Ability of CORLUX(R) to Mitigate Weight Gain Associated With Olanzapine
Corcept Therapeutics (NASDAQ: CORT) today announced that preliminary top line results indicated a statistically significant reduction in weight gain in those subjects who took olanzapine plus CORLUX compared to those who took olanzapine alone in a randomized, two week, double-blind, placebo controlled, proof of concept study.
In this study, 57 lean, healthy men (body mass index of 25 or less) were randomized to receive either olanzapine plus placebo (n=22), olanzapine plus CORLUX (n=24) or CORLUX plus placebo (n=11). This study took place in an institutional setting where daily weights were recorded and a range of metabolic parameters were measured. In the two-week study, subjects in the olanzapine alone group gained an average of 2.5 pounds more than subjects in the olanzapine plus CORLUX group and 2.2 pounds more than subjects in the CORLUX alone group, highly statistically significant differences (p < .001). The difference in weight gain trajectory was apparent in the first days of the study, reaching statistical significance during the first week. A preliminary review also indicates that for those patients who experienced a rise in fasting insulin and rise in triglycerides while taking olanzapine, the addition of CORLUX appears to have a beneficial effect; further analyses of these variables will be completed in the coming weeks. Although no unexpected study drug related adverse events were seen in any group, a complete review of all safety data has not yet been completed.
The group of medications known as atypical antipsychotics, including olanzapine, risperidone, clozapine and quetiapine, are widely used to treat schizophrenia and bipolar disorder. All medications in this group are associated with treatment emergent weight gain of varying degrees and carry a warning label relating to treatment emergent hyperglycemia and diabetes mellitus.
\"Weight gain and alterations in metabolic efficiency have been observed for many years in patients with abnormally high circulating cortisol. It is possible that a cortisol receptor antagonist like CORLUX may affect these characteristics in patients who take atypical antipsychotic medication,\" said Joseph K. Belanoff, M.D., Chief Executive Officer of Corcept. \"This study begins to give us some insight into the possible causes of weight gain associated with atypical antipsychotic medications, and potentially may lead us towards a treatment.\"
Corcept previously announced results from two preclinical studies conducted in a rat model of olanzapine induced weight gain. These studies demonstrated that CORLUX reduced both the weight gain associated with ongoing olanzapine use and prevented the weight gain associated with the initiation of treatment with olanzapine. \"Because findings in animal studies do not always translate into human experience, we are pleased to see that the effect of CORLUX in our proof of concept study appears to replicate the experimental animal data,\" said Robert L. Roe, M.D, President of Corcept.
Eli Lilly and Company supported this proof of concept clinical study through an Investigator Initiated Trial grant and provided olanzapine for the study.
The combination of olanzapine and CORLUX is not approved for any indication and Lilly has no plans to pursue the use of combination CORLUX and olanzapine commercially. The purpose of this study was to explore the hypothesis that GR-II antagonists might mitigate weight gain associated with atypical antipsychotic medications.
Intellectual Property Portfolio
Corcept has developed an extensive intellectual property portfolio that covers the use of GR-II antagonists in the treatment of severe psychotic and metabolic disorders, including the prevention of weight gain caused by the use of antipsychotic medications. The company has also discovered and filed patents for three different series of compounds which block cortisol\'s activity at the GR-II receptor but do not block the progesterone receptor. \"Eventually, we hope to test and develop our new GR-II antagonists in a wide variety of disorders including the mitigation of weight gain associated with atypical antipsychotics,\" said James N. Wilson, Chairman of the Board of Corcept.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the development of drugs for severe psychiatric and metabolic disorders. The company\'s lead program is the development of CORLUX for the treatment of the psychotic symptoms of psychotic depression. For additional information about the company, please visit www.corcept.com.
Statements made in this news release, other than statements of historical fact, are forward-looking statements, including, for example, statements relating to Corcept\'s clinical development programs, and its spending plans. Forward-looking statements are subject to a number of known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements. For example, there can be no assurances with respect to the commencement, cost, rate of spending, completion or success of clinical trials; financial projections may not be accurate; there can be no assurances that the investigations for future clinical trials will be completed, or that Corcept will pursue further activities with respect to clinical development of CORLUX. These and other risk factors are set forth in the Company\'s SEC filings, all of which are available from our website (www.corcept.com) or from the SEC\'s website (www.sec.gov). We disclaim any intention or duty to update any forward-looking statement made in this news release.
CONTACT:
Joseph K. Belanoff, M.D.
Chief Executive Officer
Corcept Therapeutics
650-327-3270
Email Contact
www.corcept.com
Source: Market Wire (June 21, 2007 - 9:00 AM EDT)
News by QuoteMedia
www.quotemedia.com
-----------------------------------------
Antwort auf Beitrag Nr.: 30.155.573 von Joe_Trader am 22.06.07 20:39:07Hingewiesen darauf wurde schon am 30.04.2007 mit diesem Artkel
----------------------------------------
Analyse/ Meinung: Corcept Therapeutics vorsichtig abfischen
Endingen (aktiencheck.de AG) - Nachzügler sollten die laufenden Pendelbewegungen zu einem vorsichtigen Abfischen von Material der Corcept-Aktie (ISIN US2183521028/ WKN 529882) nutzen, raten die Experten von "Global Insider Investing".
Die Gesellschaft befinde sich in einer ähnlichen Ausgangslage wie Biosante Ende letzten Jahres.
Corlux befinde sich derzeit in abschließenden Phase III-Tests und sei ein Präparat gegen neurologische Störungen. Werde die Effizienz und Verträglichkeit bestätigt, dürfte es zu einer Neubewertung von Corcept Therapeutics kommen.
Seit Ende letzten Jahres hätten die Experten massive Insiderkäufe bei der Aktie beobachtet. Damals habe das Papier noch bei 0,90 USD notiert und mittlerweile notiere der Wert bei knapp über 2 USD. Die Insideraktivitäten würden besonders vor dem Hintergrund interessant erscheinen, dass zwei von drei parallelen Studien zu Phase III-Tests bei Corlux erfolglos verlaufen seien. Offensichtlich würden die Insider etwas wissen oder ahnen, was die Aussichten von Corlux in einem ganz anderen Licht erscheinen lassen dürften.
Nachzügler sollten die laufenden Pendelbewegungen zu einem vorsichtigen Abfischen von Corcept-Aktien nutzen, empfehlen die Experten von "Global Insider Investing". (Ausgabe 08 vom 30.04.2007) (30.04.2007/ac/a/a)
-------------------------------------------------
Vielleicht ist das für den Einen oder Anderen die Einstiegsgelegenheit
----------------------------------------
Analyse/ Meinung: Corcept Therapeutics vorsichtig abfischen
Endingen (aktiencheck.de AG) - Nachzügler sollten die laufenden Pendelbewegungen zu einem vorsichtigen Abfischen von Material der Corcept-Aktie (ISIN US2183521028/ WKN 529882) nutzen, raten die Experten von "Global Insider Investing".
Die Gesellschaft befinde sich in einer ähnlichen Ausgangslage wie Biosante Ende letzten Jahres.
Corlux befinde sich derzeit in abschließenden Phase III-Tests und sei ein Präparat gegen neurologische Störungen. Werde die Effizienz und Verträglichkeit bestätigt, dürfte es zu einer Neubewertung von Corcept Therapeutics kommen.
Seit Ende letzten Jahres hätten die Experten massive Insiderkäufe bei der Aktie beobachtet. Damals habe das Papier noch bei 0,90 USD notiert und mittlerweile notiere der Wert bei knapp über 2 USD. Die Insideraktivitäten würden besonders vor dem Hintergrund interessant erscheinen, dass zwei von drei parallelen Studien zu Phase III-Tests bei Corlux erfolglos verlaufen seien. Offensichtlich würden die Insider etwas wissen oder ahnen, was die Aussichten von Corlux in einem ganz anderen Licht erscheinen lassen dürften.
Nachzügler sollten die laufenden Pendelbewegungen zu einem vorsichtigen Abfischen von Corcept-Aktien nutzen, empfehlen die Experten von "Global Insider Investing". (Ausgabe 08 vom 30.04.2007) (30.04.2007/ac/a/a)
-------------------------------------------------
Vielleicht ist das für den Einen oder Anderen die Einstiegsgelegenheit
ach ja, das richtige Volumen ist in den USA 
Antwort auf Beitrag Nr.: 30.155.598 von Joe_Trader am 22.06.07 20:41:27leider ist der Stock mir erst heute aufgefallen 
Antwort auf Beitrag Nr.: 30.155.620 von Joe_Trader am 22.06.07 20:43:12hoffe der eine oder andere Leser hat schnell reagiert und gekauft
sie steigt gerade wieder.
sie steigt gerade wieder.
Trading Spotlight
"hoffe der eine oder andere Leser hat schnell reagiert und gekauft"
Ich hoffe nicht .
http://biz.yahoo.com/iw/070509/0250535.html
Commenting on Corcept's financial guidance for 2007, Anne LeDoux, Corcept's Vice President and Controller, stated, "Based on the currently planned timeline of our clinical development program and our discovery research activities, we expect that cash used in operating activities in 2007 will be between $10 million and $15 million. At that pace, our current funds will enable us to continue operations through the first quarter of 2008; we will need to raise additional capital in order to fund our operations beyond that point."
Ich hoffe nicht .
http://biz.yahoo.com/iw/070509/0250535.html
Commenting on Corcept's financial guidance for 2007, Anne LeDoux, Corcept's Vice President and Controller, stated, "Based on the currently planned timeline of our clinical development program and our discovery research activities, we expect that cash used in operating activities in 2007 will be between $10 million and $15 million. At that pace, our current funds will enable us to continue operations through the first quarter of 2008; we will need to raise additional capital in order to fund our operations beyond that point."
Antwort auf Beitrag Nr.: 30.156.318 von BrauchGeld am 22.06.07 21:37:45bis dahin ist noch lange Zeit.
Denkst du nicht, ein Investor / Partner wird sich bei einer positiven Phase 3 nicht finden ??
Denkst du nicht, ein Investor / Partner wird sich bei einer positiven Phase 3 nicht finden ??
Antwort auf Beitrag Nr.: 30.156.391 von Joe_Trader am 22.06.07 21:43:52Das geld wird aber lange vor den ergebnissen weg sein,Phase 3 startet ja erst im 3Q oder 4Q .
Diese Aktie wirst du schon bald viel billiger bekommen selbst dann würde ich nicht so einen schrott kaufen.
Diese Aktie wirst du schon bald viel billiger bekommen selbst dann würde ich nicht so einen schrott kaufen.
Antwort auf Beitrag Nr.: 30.156.557 von BrauchGeld am 22.06.07 21:55:50deine Entscheidung
Der Markt sieht es z.Z. anders.
Antwort auf Beitrag Nr.: 30.156.685 von Joe_Trader am 22.06.07 22:03:11http://www.wallstreet-online.de/community/thread/1129259-1.h…
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +3,16 | |
| -0,16 | |
| +1,17 | |
| -1,42 | |
| +0,69 | |
| -0,50 | |
| +6,47 | |
| +0,55 | |
| +0,37 | |
| +0,84 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 90 | ||
| 76 | ||
| 58 | ||
| 54 | ||
| 36 | ||
| 34 | ||
| 29 | ||
| 27 | ||
| 25 |
